Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases

被引：0

作者：

Vincent Cottin

Luca Richeldi

Ivan Rosas

Maria Otaola

Jin Woo Song

Sara Tomassetti

Marlies Wijsenbeek

Manuela Schmitz

Carl Coeck

Susanne Stowasser

Rozsa Schlenker-Herceg

Martin Kolb

机构：

[1] Claude Bernard University Lyon 1,National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon

[2] University of Lyon,Pulmonary and Critical Care Medicine, Asan Medical Center

[3] INRA,Department of Experimental and Clinical Medicine

[4] UMR754,Department of Respiratory Medicine

[5] Fondazione Policlinico A. Gemelli IRCCS,undefined

[6] Università Cattolica del Sacro Cuore,undefined

[7] Baylor College of Medicine,undefined

[8] Fundación Para El Estudio de Enfermedades Fibrosantes del Pulmón,undefined

[9] University of Ulsan College of Medicine,undefined

[10] Careggi University Hospital,undefined

[11] Erasmus MC,undefined

[12] University Medical Centre,undefined

[13] Mainanalytics GmbH,undefined

[14] SCS Boehringer Ingelheim Comm.V.,undefined

[15] Boehringer Ingelheim International GmbH,undefined

[16] Boehringer Ingelheim Pharmaceuticals,undefined

[17] Inc.,undefined

[18] McMaster University and St. Joseph’s Healthcare,undefined

来源：

Respiratory Research | / 22卷

关键词：

Pulmonary fibrosis; Connective tissue diseases; Autoimmune diseases; Corticosteroids; Immunosuppressants;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 54 条

[1]

Raghu G(2018)Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline Am J Respir Crit Care Med 198 e44-e68

[2]

Remy-Jardin M(2018)What’s in a name? That which we call IPF, by any other name would act the same Eur Respir J 51 1800692-699

[3]

Myers JL(2018)Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases Eur Respir Rev 27 180076-2024

[4]

Wells AU(2019)The natural history of progressive fibrosing interstitial lung diseases Respir Res 20 57-1727

[5]

Brown KK(2020)The natural history of progressive fibrosing interstitial lung diseases Eur Respir J 55 2000085-460

[6]

Flaherty KR(2018)Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study J Clin Med 8 14-2528

[7]

Kolb M(2017)Diagnosis and treatment of fibrotic hypersensitivity pneumonia. Where we stand and where we need to go Am J Respir Crit Care Med 196 690-2082

[8]

Thannickal VJ(2019)Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management Curr Med Res Opin 35 2015-1977

[9]

Cottin V(2019)Nintedanib in progressive fibrosing interstitial lung diseases N Engl J Med 381 1718-undefined

[10]

Hirani NA(2020)Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial Lancet Respir Med 8 453-undefined

← 1 2 3 4 5 6 →